Climate change to quadruple air quality alerts, challenging adaptation in vulnerable U.S. communities

Three months af­ter a large study of No­vo Nordisk’s pop­u­lar weight-loss and di­a­betes in­jec­tion showed it cut ma­jor car­dio­vas­cu­lar risks by 20%, fur­ther re­sults from

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes